The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades. The daily pills will be sold by Revolution Medicines under the brand name Rasonque.